Education
About Us
Working with TipRanks
Follow Us
Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
Total Valuation
Intra-Cellular Therapies has a market cap or net worth of $14.05B. The enterprise value is ―.
Market Cap$14.05B
Enterprise Value―
Share Statistics
Intra-Cellular Therapies has 55,261,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding55,261,000
Owned by Insiders1.37%
Owned by Institutions28.29%
Financial Efficiency
Intra-Cellular Therapies’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -10.08%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-10.08%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee791.69K
Profits Per Employee-86.83K
Employee Count860
Asset Turnover0.50
Inventory Turnover2.17
Valuation Ratios
The current PE Ratio of Intra-Cellular Therapies is -115.34. Intra-Cellular Therapies’s PEG ratio is -11.31.
PE Ratio-115.34
PS Ratio20.56
PB Ratio11.84
Price to Fair Value7.50
Price to FCF-191.03
Price to Operating Cash Flow-185.76
PEG Ratio-11.31
Income Statement
In the last 12 months, Intra-Cellular Therapies had revenue of 680.85M and earned -74.68M in profits. Earnings per share was -0.72.
Revenue680.85M
Gross Profit623.89M
Operating Income-116.72M
Pretax Income-74.20M
Net Income-74.68M
EBITDA-116.72M
Earnings Per Share (EPS)-0.72
Cash Flow
In the last 12 months, operating cash flow was -73.18M and capital expenditures -322.00K, giving a free cash flow of -73.50M billion.
Operating Cash Flow-73.18M
Free Cash Flow-73.50M
Free Cash Flow per Share-1.33
Dividends & Yields
Intra-Cellular Therapies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change101.88%
50-Day Moving Average129.61
200-Day Moving Average93.30
Relative Strength Index (RSI)84.54
Average Volume (3m)2.42M
Important Dates
Intra-Cellular Therapies upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateFeb 21, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Intra-Cellular Therapies as a current ratio of 6.36, with Debt / Equity ratio of 1.48%
Current Ratio6.36
Quick Ratio6.23
Debt to Market Cap<0.01
Net Debt to EBITDA2.48
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Intra-Cellular Therapies has paid 473.00K in taxes.
Income Tax473.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Intra-Cellular Therapies EV to EBITDA ratio is -71.31, with an EV/FCF ratio of -113.25.
EV to Sales12.23
EV to EBITDA-71.31
EV to Free Cash Flow-113.25
EV to Operating Cash Flow-113.75
Balance Sheet
Intra-Cellular Therapies has $1.00B in cash and marketable securities with $16.98M in debt, giving a net cash position of -$984.09M billion.
Cash & Marketable Securities$1.00B
Total Debt$16.98M
Net Cash-$984.09M
Net Cash Per Share-$17.81
Tangible Book Value Per Share$11.14
Margins
Gross margin is 91.63%, with operating margin of -17.14%, and net profit margin of -10.97%.
Gross Margin91.63%
Operating Margin-17.14%
Pretax Margin-10.90%
Net Profit Margin-10.97%
EBITDA Margin-17.14%
EBIT Margin-17.14%
Analyst Forecast
The average price target for Intra-Cellular Therapies is $130.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$130.83
Price Target Upside-0.79% Downside
Analyst ConsensusModerate Buy
Analyst Count13
Revenue Growth Forecast46.62%
EPS Growth Forecast50.50%